G1 is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of cancer. The Company focuses on cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells, and represents a recently validated and promising class of targets for anti-cancer therapeutics.
TypePublic
HQDurham, US
Founded2008
Size (employees)44 (est)+16%
Websiteg1therapeutics.com
G1 Therapeutics was founded in 2008 and is headquartered in Durham, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at G1 Therapeutics

Mark Velleca

Mark Velleca

CEO
Rajesh Malik

Rajesh Malik

Chief Medical Officer
Jay Strum

Jay Strum

Chief Scientific Officer
Greg Mossinghoff

Greg Mossinghoff

Chief Business Officer
Show more

G1 Therapeutics Office Locations

G1 Therapeutics has an office in Durham
Durham, (HQ)
79 T.W. Alexander Dr.
Show all (1)
Report incorrect company information

G1 Therapeutics Financials and Metrics

G1 Therapeutics Revenue

USD

Net income (Q2, 2018)

(20.9m)

EBIT (Q2, 2018)

(21.7m)

Market capitalization (4-Dec-2018)

1.3b

Closing stock price (4-Dec-2018)

34.5

Cash (30-Jun-2018)

188.2m
G1 Therapeutics's current market capitalization is $1.3 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

522.0k

Revenue growth, %

(100%)

General and administrative expense

3.2m5.2m7.1m

R&D expense

12.7m25.2m53.9m
Quarterly
USDQ3, 2017Q2, 2018

General and administrative expense

1.9m3.3m

R&D expense

14.1m18.4m

Operating expense total

15.9m21.7m

EBIT

(15.9m)(21.7m)
Annual
USDFY, 2016FY, 2017

Cash

47.3m103.8m

Prepaid Expenses

596.0k849.0k

Current Assets

47.9m104.7m

PP&E

311.0k510.0k
Quarterly
USDQ3, 2017Q2, 2018

Cash

118.4m188.2m

Current Assets

119.0m189.9m

PP&E

516.0k711.0k

Total Assets

119.6m190.6m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(20.3m)(30.3m)(60.1m)

Depreciation and Amortization

42.0k67.0k89.0k

Accounts Payable

1.7m3.4m6.3m

Cash From Operating Activities

(13.8m)(25.1m)(50.5m)
Quarterly
USDQ3, 2017

Net Income

(43.1m)

Depreciation and Amortization

59.0k

Accounts Payable

5.0m

Cash From Operating Activities

(35.8m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

G1 Therapeutics News and Updates

G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2018 (GLOBE NEWSWIRE) --  G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with chemotherap…

G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic …

G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update

Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib

G1 Therapeutics to Present at Investor Conferences in November 2018

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in Novembe…

G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2018 on Wednesday, November …

G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced data from new analyses of its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for the treatment of fir…
Show more
Report incorrect company information

G1 Therapeutics Company Life and Culture

Report incorrect company information

G1 Therapeutics Frequently Asked Questions

  • When was G1 Therapeutics founded?

    G1 Therapeutics was founded in 2008.

  • Who are G1 Therapeutics key executives?

    G1 Therapeutics's key executives are Mark Velleca, Rajesh Malik and Jay Strum.

  • How many employees does G1 Therapeutics have?

    G1 Therapeutics has 44 employees.

  • Who are G1 Therapeutics competitors?

    Competitors of G1 Therapeutics include PDL BioPharma, GTx and Burzynski Research Institute.

  • Where is G1 Therapeutics headquarters?

    G1 Therapeutics headquarters is located at 79 T.W. Alexander Dr., Durham.

  • Where are G1 Therapeutics offices?

    G1 Therapeutics has an office in Durham.

  • How many offices does G1 Therapeutics have?

    G1 Therapeutics has 1 office.